

[Allopurinol](#)

Essential medicine status

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.5. Supportive medicines](#)

ATC codes: [M04AA01](#)

EMLc

Indication

Tumour lysis syndrome ICD11 code: [5C70](#)

INN

Allopurinol

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > IV: 500 mg (as sodium) powder for injection (EMLc)

Oral > Solid: 100 mg (EMLc) ; 300 mg (EMLc)

EML status history

First added in 2007 ([TRS 950](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Children (1 month - 12 years)

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer supportive care

Wikipedia

[Allopurinol](#)

DrugBank

[Allopurinol](#)

Summary of evidence and Expert Committee recommendations



Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of allopurinol powder for injection 500 mg to the EMLc for use in the prophylaxis and treatment of tumour lysis syndrome.